Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Panobinostat Plus ICE for Relapsed/Refractory Classical Hodgkin Lymphoma
NCT01169636Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jan 2011
- Primary completion
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of panobinostat in classical Hodgkin lymphoma (cHL), sponsored by University of Texas MD Anderson Cancer Center. Started Jan 2011; status: completed.
02
Drugs
panobinostat
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on NCT01169636.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01169636.